loading
Precedente Chiudi:
$11.30
Aprire:
$11.25
Volume 24 ore:
590.07K
Relative Volume:
0.95
Capitalizzazione di mercato:
$706.46M
Reddito:
-
Utile/perdita netta:
$-156.39M
Rapporto P/E:
-3.1287
EPS:
-3.69
Flusso di cassa netto:
$-123.06M
1 W Prestazione:
-1.11%
1M Prestazione:
-1.95%
6M Prestazione:
+36.60%
1 anno Prestazione:
-2.69%
Intervallo 1D:
Value
$11.15
$11.90
Intervallo di 1 settimana:
Value
$11.10
$12.17
Portata 52W:
Value
$7.30
$15.50

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name
Nome
Kalvista Pharmaceuticals Inc
Name
Telefono
(857) 999-0075
Name
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Dipendente
150
Name
Cinguettio
@kalvista
Name
Prossima data di guadagno
2025-03-12
Name
Ultimi documenti SEC
Name
KALV's Discussions on Twitter

Confronta KALV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
KALV
Kalvista Pharmaceuticals Inc
11.55 706.46M 0 -156.39M -123.06M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.69 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
539.04 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.30 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
548.28 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
243.38 28.51B 3.81B -644.79M -669.77M -6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-31 Iniziato JMP Securities Mkt Outperform
2025-01-07 Iniziato TD Cowen Buy
2024-12-18 Iniziato BofA Securities Buy
2020-06-15 Iniziato H.C. Wainwright Buy
2019-07-29 Iniziato SVB Leerink Outperform
2019-03-20 Iniziato Needham Buy
2018-10-30 Iniziato Jefferies Buy
2018-09-21 Iniziato Cantor Fitzgerald Overweight
2017-08-31 Iniziato BTIG Research Buy
Mostra tutto

Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie

pulisher
Jun 16, 2025

FDA delays Kalvista’s sebetralstat decision due to resource constraints By Investing.com - Investing.com Nigeria

Jun 16, 2025
pulisher
Jun 16, 2025

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’ - BioPharma Dive

Jun 16, 2025
pulisher
Jun 16, 2025

FDA delays Kalvista’s sebetralstat decision due to resource constraints - Investing.com

Jun 16, 2025
pulisher
Jun 16, 2025

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Pat - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

KalVista’s oral HAE treatment shows efficacy for breakthrough attacks By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

DRI Healthcare Notes FDA Delay for KalVista's' Sebetralstat New Drug Approval on "Resourcing" Issues - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Kalvista stock steady as JMP reiterates $19 target amid FDA delay - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Kalvista stock steady as JMP reiterates $19 target amid FDA delay By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

DRI Healthcare Trust Reports FDA Delay on KalVista’s Sebetralstat Decision - MSN

Jun 16, 2025
pulisher
Jun 14, 2025

FDA won’t meet PDUFA goal date for sebetralstat - The Pharma Letter

Jun 14, 2025
pulisher
Jun 13, 2025

DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals' Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints - Weekly Voice

Jun 13, 2025
pulisher
Jun 13, 2025

US FDA extends review of KalVista's swelling disorder drug due to heavy workload - Reuters

Jun 13, 2025
pulisher
Jun 13, 2025

FDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval Decision - Bloomberg

Jun 13, 2025
pulisher
Jun 13, 2025

FDA cites ‘resource constraints' in delay of local biotech's drug approval decision - The Business Journals

Jun 13, 2025
pulisher
Jun 13, 2025

KalVista (KALV) Shares Decline as FDA Delays Drug Review - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

FDA delays decision on KalVista’s HAE treatment sebetralstat By Investing.com - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

KalVista said FDA will not meet review date for sebetralstat (KALV) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

KalVista (KALV) Awaits FDA Decision on Sebetralstat Due to Revie - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Kalvista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date For Sebetralstat NDA - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints | KALV Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints - Business Wire

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Has $114,000 Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

KALV’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com

Jun 12, 2025
pulisher
Jun 12, 2025

Research Analysts Issue Forecasts for KALV FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Sells 15,500 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Bank of America Corp DE Has $932,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Buy” from Analysts - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Transcript : KalVista Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - MarketScreener

Jun 06, 2025
pulisher
Jun 05, 2025

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 - BioSpace

Jun 05, 2025
pulisher
Jun 05, 2025

KalVista Pharmaceuticals to Present New Sebetralstat Data at the - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 | KALV Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ameriprise Financial Inc. Takes $452,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Purchases New Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 - BioSpace

Jun 04, 2025
pulisher
Jun 03, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Has $53,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

(KALV) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 02, 2025

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

KalVista (KALV) Shows Promising Sebetralstat Results for Heredit - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

KalVista (KALV) Shows Promising Sebetralstat Results for Hereditary Angioedema | KALV Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

KalVista Pharmaceuticals Medical Congress Presentations Highligh - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management | KALV Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Reduces Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Deutsche Bank AG Grows Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jun 01, 2025
pulisher
May 29, 2025

KalVista Pharmaceuticals to Present at the Jefferies Global Heal - GuruFocus

May 29, 2025
pulisher
May 29, 2025

KalVista Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - BioSpace

May 29, 2025
pulisher
May 29, 2025

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire

May 29, 2025

Kalvista Pharmaceuticals Inc Azioni (KALV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Kalvista Pharmaceuticals Inc Azioni (KALV) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Audhya Paul K.
CHIEF MEDICAL OFFICER
May 23 '25
Sale
11.31
2,146
24,272
113,026
Yea Christopher
CHIEF DEVELOPMENT OFFICER
May 23 '25
Sale
11.31
1,926
21,782
98,189
Audhya Paul K.
CHIEF MEDICAL OFFICER
May 22 '25
Sale
11.88
2,689
31,933
110,172
Yea Christopher
CHIEF DEVELOPMENT OFFICER
May 22 '25
Sale
11.88
2,317
27,516
96,990
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
May 22 '25
Sale
11.88
9,999
118,743
306,618
Yea Christopher
CHIEF DEVELOPMENT OFFICER
May 19 '25
Sale
11.84
2,600
30,791
95,557
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
May 19 '25
Sale
11.84
3,808
45,097
293,367
Audhya Paul K.
CHIEF MEDICAL OFFICER
May 19 '25
Sale
11.84
2,776
32,876
106,611
Venrock Healthcare Capital Par
10% Owner
Apr 09 '25
Buy
9.42
25,000
235,500
5,303,985
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER
Mar 07 '25
Sale
11.97
6,669
79,828
287,811
$20.77
price up icon 0.61%
$35.84
price down icon 0.56%
$21.20
price down icon 0.47%
$97.54
price down icon 3.04%
$108.01
price up icon 1.45%
biotechnology ONC
$243.88
price up icon 0.76%
Capitalizzazione:     |  Volume (24 ore):